Pathways to the diagnosis of prostate cancer in a British city. A population-based study

Scandinavian Journal of Urology and Nephrology

Volumn 39, Issue 4, 2005, Pages 267-270

  Barrett, Jacqueline ^a   Hamilton, William ^b  

^a Barnfield Hill Research Practice   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Pathways; Prostate cancer; Prostate specific antigen; Symptoms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL PATHWAY; DIGITAL RECTAL EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; UNITED KINGDOM; URINARY TRACT DISEASE;

ADULT; AGED; AGED, 80 AND OVER; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; URINATION DISORDERS;

EID: 27144453703     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590510031282     Document Type: Article

References (19)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003; 361:859-64.
2. Murphy M, Johnston C, Whelan P, Rider L, Lloyd SN. Changing trends in prostatic cancer. BJU Int 1999;83:786-91.
3. Tannock I. Eradication of a disease: how we cured symptomless prostate cancer. Lancet 2002;359:1341-2.
4. Quinn M, Babb P, Brock A, Jones J. Cancer trends in England and Wales 1950-1999. London: The Stationery Office; 2001.
5. Horwich A, Waxman J, Abel P, Laniado M, Dearnaley D. Tumours of the prostate. In: Souhami R, et al, editors. The Oxford textbook of oncology, 2nd ed. Oxford, UK: Oxford University Press; 2001. p. 1939-71.
6. Ornstein DK, Rao GS, Smith DS, Andriole GL. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia under-going transurethral resection of the prostate. J Urol 1997; 157:880-3.
7. Shibata A, Ma J, Whittemore A. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 1998;90:1230-1.
8. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-94.
9. Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev 2001;23:181-6.
10. Walsh PC. Surgery and the reduction of mortality from prostate cancer. N Engl J Med 2002;347:839-40.
11. Stattin P, Johansson R, Damber J-E, Hellstrom M, Hugosson J, Lundgren R, et al. Non-systematic screening for prostate cancer in Sweden. Scand J Urol Nephrol 2003;37: 461-5.
12. Gjengsto P, Eide J, Frugard J, Bakke A, Hoisaeter PA. The potentially curable prostate cancer patient and the pathways leading to diagnosis and treatment. Scand J Urol Nephrol 2004;38:15-8.
13. Selley S, Donovan JL, Faulkner A, Coast J, Gillatt D. Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess 1997;2:1-96.
14. NHS Centre for Reviews and Dissemination. Screening for prostate cancer. Effectiveness Matters 1997;2:1-4.
15. Chamberlain J, Melia J, Moss SM, Brown J. The diagnosis, management, treatment and costs of prostate cancer in England and Wales. Health Technol Assess 1997;1:1-53.
16. Farmer A. 10-minute consultation: prostatic symptoms. Br Med J 2001;322:1468.
17. Etzioni R, Cha R, Feuer EJ, Davidov O. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol 1998;148:775-85.
18. Chokkalingam AP, Nyren O, Johansson JE, Gridley G, McLaughlin JK, Adami HO, et al. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden. Cancer 2003;98: 1727-34.
19. Wilkinson S, Chodak G. Informed consent for prostatespecific antigen screening. Urology 2003;61:2-4.